Antiretrovirals and Risk of COVID-19 Diagnosis and Hospitalization in HIV-Positive Persons

del Amo, Julia; Polo, Rosa; Moreno, Santiago; Díaz, Asunción; Martínez, Esteban; Arribas, José Ramón; Jarrín, Inma; Hernán, Miguel A.

doi:10.1097/EDE.0000000000001235

del Amo, Julia; Polo, Rosa; Moreno, Santiago; Díaz, Asunción; Martínez, Esteban; Arribas, José Ramón; Jarrín, Inma; Hernán, Miguel A.

Statistics

View Usage Statistics

Identifiers

URI: http://hdl.handle.net/20.500.11940/15661

PMID: 32773469

DOI: 10.1097/EDE.0000000000001235

ISSN: 1044-3983

Full record

Services

Files view or download

Epidemiology. 2020 Nov;31(6):e49-e51 (109.4Kb)

Corporate author

The Spanish HIV/COVID-19 Collaboration

Date issued

2020

Journal title

Epidemiology

Type of content

Artigo

DeCS

VIH | incidencia | conducta cooperativa | riesgo | inhibidores de la integrasa

MeSH

Risk | Integrase Inhibitors | Cooperative Behavior | HIV | Incidence

Abstract

The risk of COVID-19 diagnosis and hospitalization among HIV-positive individuals is lower in those receiving treatment with TDF/FTC than in those receiving other ART regimes. This association does not seem to be explained by confounding due to unmeasured clinical characteristics. Our finding is compatible with accumulating evidence on a potential effect of TDF/FTC against SARS-CoV-2 infection.

RUNA digital repository